Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy

Nephrology

Volumn 15, Issue 8, 2010, Pages 762-767

  Kalliakmani, Pantelitsa ^a   Koutroulia, Eleni ^a   Sotsiou, Florentia ^a   Vlachojannis, John G ^a   Goumenos, Dimitrios S ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

cyclosporin; membranous nephropathy; nephrotic syndrome; repeat renal biopsies

Indexed keywords

CYCLOSPORIN A; PREDNISOLONE;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COST BENEFIT ANALYSIS; CUSHINGOID SYNDROME; DISEASE COURSE; DRUG EFFICACY; FEMALE; GINGIVA HYPERPLASIA; GLOMERULOSCLEROSIS; HERPES ZOSTER; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTOXICITY; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; COST-BENEFIT ANALYSIS; CYCLOSPORINE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PREDNISOLONE; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 78650661711     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01301.x     Document Type: Article

References (20)

1. Muirhead N,. Management of idiopathic membranous nephropathy: Evidence-based recommendations. Kidney Int. 1999; 55 (S70): S47-55.
2. Cattran DC,. Idiopathic membranous glomerulonephritis. Kidney Int. 2001; 59: 1983-94.
3. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995; 48: 1600-604.
4. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 1998; 9: 444-50.
5. De Santo NG, Capodicasa G, Giordano C,. Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. Am. J. Nephrol. 1987; 7: 74-6.
6. Cattran DC, Appel GB, Hebert LA, et al., Kunis CL for the North American Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int. 2001; 59: 1484-90.
7. Goumenos DS, Kalliakmani P, Tsakas S, Sotsiou F, Vlachojannis JG,. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin. Nephrol. 2004; 61: 17-24.
8. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D,. Induction and long-term treatment with cyclosporin in membranous nephropathy with the nephrotic syndrome. Nephrol. Dial. Transplant. 2006; 21: 3127-32.
9. Ponticelli C, Passerini P,. The place of cyclosporin in the management of primary nephrotic syndrome. BioDrugs 1999; 12: 327-41.
10. Meyrier A, Noël L-H, Aurishe P, Callard P, the Collaborative Group of the Société de Néphrologie, with the technical assistance of Broneer D. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephritic syndrome. Kidney Int. 1994; 45: 1446-56.
11. Schwartz MM,. Membranous GN. In:, Jennette JC, Olson JL, Schwartz MM, Silva FG, (eds). Heptinstall's Pathology of the Kidney, Vol. 1, 5th edn. Philadelphia, PA: Lippincott-Raven Publishers, 1998; 259-307.
12. Perna A, Schiepati A, Zamora J, Guiliano GA, Braun N, Remuzzi G,. Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. Am. J. Kidney Dis. 2004; 44: 385-401.
13. Cattran DC, Delmore T, Roscoe J, et al. A randomized controlled trial of prednisolone in idiopathic membranous nephropathy. N. Engl. J. Med. 1989; 320: 210-325.
14. Cameron JS, Healy MJR, Adu D,. The Medical Research Council trial of short-term high-dose alternate-day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q. J. Med. 1990; 74: 133-56.
15. Goumenos DS, Ahuja M, Davlouros P, El Nahas AM, Brown CB,. Prednisolone and azathioprine in membranous nephropathy. A ten-year follow-up study. Clin. Nephrol. 2006; 65: 317-23.
16. Goumenos DS, Katopodis K, Passadakis P, et al. Corticosteroids and cyclosporin-A in idiopathic membranous nephropathy: Higher remission rate of nephritic syndrome and less adverse reactions than the traditional treatment with cytotoxic drugs. Am. J. Nephrol. 2007; 27: 226-31.
17. Fritsche L, Budde K, Farber L, et al. Treatment of membranous glomerulopathy with cyclosporin A: How much patience is required? Nephrol. Dial. Transplant. 1999; 14: 1036-8.
18. Zucchelli P, Pascuali S, Casanova S, Donini U,. Clinical and morphological evolution of idiopathic membranous nephropathy. Clin. Nephrol. 1986; 25: 282-288.
19. Pierides AM, Malasit P, Morley AR, Wilkinson R, Uldall PR, Kerr DNS,. Idiopathic membranous nephropathy. Q. J. Med. 1977; 182: 163-77.
20. Ambalavanan S, Fauvel JP, Sibley RK, Myers BD,. Mechanism of the antiproteinuric effect of cyclosporin in membranous nephropathy. J. Am. Soc. Nephrol. 1996; 7: 290-98.